flosz schreef:
Jaja....dit zijn Crucellige tijden.
Mr. Vasella=Novartis.
An immediate priority, Mr. Vasella said, will be to improve Chiron's operations. "We first want to fix the quality and quantity problems, which are at hand," he said.
For one, Novartis plans to improve the way vaccines are developed. Currently companies use eggs to manufacture vaccines, a slow process that can lead to contamination. Mr. Vasella said Novartis was looking at expanding cell-based vaccine production, which can be more efficient.
Mr. Vasella said Novartis was pursuing vaccines as an important growth area. Unlike many drugs, which have come under price pressure from copy-cat producers, vaccines are underpriced and have room to rise, he said.
www.mezomorf.com/health/news-10244.html*******************************************************
Novartis AG, Europe's second-largest drugmaker, has already agreed to spend more than $13 billion on acquisitions this year and said it is looking at all potential targets to expand its product range. Novartis spokeswoman Corinne Hoff declined to comment.